ArticleESC heart failure2025
Socioeconomic determinants of vaccination against pneumococcus in 763 945 patients with heart failure.
Article in ESC heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Contributing Factors to Infectious Disease Risk and Vaccine Strategy Optimization in Cardiac Surgery Patients.Vaccines · 2026Review
- A Survey of Healthcare Professionals' Awareness of Vaccination in Patients With Heart Failure.International journal of heart failure · 2026Article
- Socioeconomic determinants of vaccination against pneumococcus in 763 945 patients with heart failure.ESC heart failure · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Respiratory infections are the leading cause of acute decompensation, hospitalization and higher mortality in heart failure (HF) patients. Despite recommendations, vaccination coverage against pneumococcus and influenza remains alarmingly low (3% and 50% in 2018, respectively). This study aimed to identify factors associated with vaccination among HF patients using data from the Nationwide Health Claims Database for 2020, in France. The patients were followed during the entire year 2020. At least one dose of PCV13 was considered as a proxy for vaccination. The model used was a multivarable logistic regression. Among 763 945 HF patients (mean age 76.7 years, 54.2% male), the mean annual visits were 7.0 with a general practitioner, 1.68 with a specialist and 70.0 with a nurse. Despite frequent healthcare contacts, vaccination coverage was only 12.6% for pneumococcus (PCV13) and 63.1% for influenza. In multivariable analyses, at least one dose of the PCV13 was less often received when patients were (1) older (odd ratio (OR): 0.71 [0.67; 0.74], P < 0.0001 and 0.48 [0.46; 0.51], P < 0.0001) in patients 76-85 and older than 85 years old, respectively, (2) women (OR: 0.916 [0.903; 0.929], P < 0.0001) or 3/when they presented social deprivation (for the quintile Q5 of deprivation index, OR was 0.893 [0.872; 0.914], P < 0.0001). Pneumoccocus vaccination was associated with influenza vaccination or with better access to health services. We need to consider factors, such as age, sex and social deprivation, to adapt public health initiatives supporting a significantly and sustainably increase pneumococcal vaccination coverage in frail HF patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.